Wil Helmus schreef op 17 juni 2020 19:04:
[...]
Op clinicaltrails staat het volgende:
There will be two parts to this study: a dose escalation phase (1) and a dose expansion phase (2a).
The aim of the dose escalation phase is to determine the maximum tolerated dose (MTD) and establish the recommended Phase 2a dose (RP2D).
The dose escalation phase will be followed by the dose expansion phase once the MTD/RP2D of AFM24 monotherapy has been determined. The dose expansion phase of the study using the MTD/P2D is intended to collect preliminary evidence of efficacy and to further confirm the safety of AFM24 as a monotherapy. The expansion phase will have 4 arms based on tumor type of metastatic colorectal cancer and non-small cell lung cancer.
Wordt hier ook niet vermeld dat er in de ascalation fase geen verandering van het ziekteverloop te verwachten valt. Nou ja, laten we Onno maar geloven op zijn zongebruinde teint.... ;-)